All news

PTC Therapeutics VP sells 1,638 shares under 10b5-1 plan

Alpha Vantage · MarketBeat · · AI-summarised by FinFlash

PTC Therapeutics VP Mark Boulding sold 1,638 shares of the company's stock for

Read original source

PTCT company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.